Lu AF27139 是一种有效的、选择性的、具有口服活性的 P2X7 受体拮抗剂（IC₅₀s 值对人和大鼠分别为 12 和 2.4 nM，K_is 对小鼠、人和大鼠分别为 22、54 和 13 nM ）。Lu AF27139 具有啮齿动物活性和 CNS 渗透特性。Lu AF27139 具有研究中枢神经系统疾病的潜力。

Lu AF27139 is a potent, selective, and orally active antagonist of P2X7 receptor (IC 50 s of 12 and 2.4 nM for human and rat, K i s of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 has rodent-active and CNS-penetrant character. Lu AF27139 has the potential for the research of CNS diseases.

Solid

P2X7

Lu AF27139 (compound 1) (10-200 nM) inhibits 100 μM BzATP-induced current in HEK293 cells stably transfected with the rat P2X7R in a dose response manner with an IC50 of 66 nM.
Lu AF27139 (compound 1) (100 nM) inhibits 300 μM BzATPinduced current in primary rat microglia with 80% inhibition occurring at a 100 nM dose.
Lu AF27139 (compound 1) inhibits LPS-primed and BzATP-induced IL-1β release from THP-1 cells with an IC50 of 38 ± 2.5 nM.
Lu AF27139 (compound 1) concentration-dependently blocks IL-1β release in rat and mouse primary cortical microglia primed with LPS and induces with 1 mM BzATP with IC50’s of 38 ± 19 nM in rat and 26 ± 6 nM in mice. has not independently confirmed the accuracy of these methods. They are for reference only.

Lu AF27139 (compound 1) (p.o.; 3, 10, and 100 mg/kg) reduces intracerebroventricular (icv) administered LPS-primed and BzATP-triggered IL-1β release in the frontal cortex of rats and mice.
Assessment of Pharmacokinetics (PK) profile of Lu AF27139 (compound 1) in rat.
dose C u, plasma (nM)

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Hopper AT, et al. Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. J Med Chem. 2021;64(8):4891-4902.

In Vitro: DMSO : 125 mg/mL (251.04 mM; Need ultrasonic)配制储备液